Kirchheimer J, Binder B R
Haemostasis. 1983;13(6):358-62. doi: 10.1159/000214822.
In tissue sections of human hyperplastic as well as carcinomatous prostate glands fibrinolytic activity could be attributed to collecting ducts and vessel walls. Inhibition studies with antibodies directed against human urokinase (u-PA) or tissue plasminogen activator (t-PA) revealed the presence of a plasminogen activator completely inhibitable by anti-t-PA IgG in the vessel walls, while in collecting ducts the plasminogen activator activity was inhibited by anti-u-PA IgG to only 80% and by anti-t-PA IgG to about 20%. A mixture of anti-u-PA and anti-t-PA IgG was able to inhibit fibrinolytic activity in collecting ducts completely. In carcinomatous prostate glands total fibrinolytic activity was significantly higher, but localization and relative contribution of anti-u-PA-inhibitable and anti-t-PA-inhibitable plasminogen activators remained the same.
在人类增生性前列腺以及癌性前列腺组织切片中,纤维蛋白溶解活性可归因于集合管和血管壁。用针对人尿激酶(u-PA)或组织型纤溶酶原激活剂(t-PA)的抗体进行的抑制研究表明,血管壁中存在一种完全可被抗t-PA IgG抑制的纤溶酶原激活剂,而在集合管中,纤溶酶原激活剂活性被抗u-PA IgG抑制至仅80%,被抗t-PA IgG抑制至约20%。抗u-PA和抗t-PA IgG的混合物能够完全抑制集合管中的纤维蛋白溶解活性。在癌性前列腺中,总纤维蛋白溶解活性显著更高,但抗u-PA可抑制和抗t-PA可抑制的纤溶酶原激活剂的定位和相对贡献保持不变。